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Abstract
Introduction: Superior mesenteric artery syndrome is a rare cause of upper intestinal obstruction resulting from
compression of the duodenum by the superior mesenteric artery and abdominal aorta.
Case presentation: We describe a case of superior mesenteric artery syndrome in a 61-year-old Japanese man
with non-small cell lung cancer who had been treated with cisplatin-containing chemotherapy and had lost 7 kg
in weight. The diagnosis was confirmed by the typical findings of abdominal computed tomography showing
distended stomach resulting from compression of the third portion of the duodenum and reduction of an
aortomesenteric distance and aortomesenteric angle.
Conclusions: This case highlights the importance of considering the possibility of superior mesenteric artery
syndrome in patients treated with chemotherapy, especially those presenting with a low body mass index and
showing weight loss during chemotherapy.
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Introduction
Superior mesenteric artery (SMA) syndrome, also
known as Wilkie’s syndrome, is a rare cause of upper
gastrointestinal obstruction. In the SMA syndrome, the
third portion of the duodenum is trapped between the
abdominal aorta and the SMA. The clinical symptoms
include postprandial epigastric pain, nausea, vomiting,
anorexia, and weight loss due to duodenal obstruction
[1]. SMA syndrome is directly related to anatomical and
mechanical factors. In contrast to the position of four-
legged mammals, the aortomesenteric angle in humans
changes from 90° to an accentuated acute angle, leading
to vascular constriction at the location where the duode-
num usually crosses thereby triggering the syndrome. In
addition, the development of SMA syndrome is gener-
ally associated with acute or chronic reduction of retro-
peritoneal fat [2]. Numerous predisposing conditions for
SMA syndrome, such as cancer, trauma, anorexia ner-
vosa, and postoperative states, have been identified with
potential impacts on the aortomesenteric angle. How-
ever, SMA syndrome has rarely been reported in
patients treated with systemic chemotherapy. We report
the case of a patient with non-small cell lung cancer
(NSCLC) treated with cisplatin-containing chemother-
apy who developed typical clinical and radiological find-
ings of duodenal obstruction due to SMA syndrome.
The patient experienced weight loss because of severe
emesis after the initiation of chemotherapy. Our experi-
ence suggests that SMA syndrome could be present in
patients receiving systemic chemotherapy.
Case Presentation
A 61-year-old Japanese man with weight 49.6 kg and
height 1.68 m (body mass index (BMI) = 17.6 kg/m
2)
was diagnosed with stage IIIB squamous cell carcinoma
of the lung in March 2009. He lost 3 kg in body weight
o v e rap e r i o do fs i xm o n t h s .H eu n d e r w e n to n ec o u r s e
of systemic chemotherapy (cisplatin at 80 mg/m
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2 on day one). He was treated pro-
phylactically with dexamethasone and granisetron for
antiemesis just before the chemotherapy. From day
three to day 10 after the initiation of chemotherapy, he
had anorexia, nausea and vomiting, estimated as grade
three according to the common terminology criteria for
adverse event, Version 4, and lost 4 kg in weight. On
day 17, he presented with epigastric pain and vomiting.
Physical examination showed a distended abdomen and
decreased bowel sound. Plain abdominal X-ray showed a
distended stomach and duodenal gas (Figure 1). Con-
trast-enhanced abdominal computed tomography (CT)
showed a distended stomach and duodenal bulb due to
compression of the third portion of the duodenum, an
aortomesenteric distance of 6.1 mm (normal: 10 to 28
mm) and a reduction of the aortomesenteric angle to
15.8° (normal: 25° to 60°) (Figure 2) [3]. These findings
were highly suggestive of SMA syndrome.
An upper gastrointestinal series in the supine position
showed a sharp cut-off at the third portion of the duode-
num (Figure 3A). In the prone position, the contrast med-
ium passed through the obstructed part of the distal side
of the third portion of duodenum (Figure 3B). After insert-
ing a nasogastric tube, more than 2700 mL turbid, green
fluid was drained. His symptoms improved after nasogas-
tric tube drainage and he remained in the prone position.
The patient was given total parenteral nutrition for 10
days and tubal feeding for the following 10 days. After 20
Figure 1 Abdominal X-ray showed distension sign of the stomach with air fluid level and duodenal gas.
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he returned to oral intake without subsequent symptoms.
Subsequent chemotherapy using the same regimen was
started after his body weight reached more than 50 kg. He
presented with grade 2 emesis during chemotherapy but
developed neither SMA syndrome nor weight loss. A total
of four cycles of chemotherapy were performed, and the
patient achieved a partial response.
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Figure 2 Abdominal computed tomography. Abdominal computed tomography showed distension of the stomach and the duodenal bulb
due to compression of the third portion of duodenum. The distance between the abdominal aorta and superior mesenteric artery was 6.1 mm
(A). The angle between the abdominal aorta and superior mesenteric artery was 15.8° (B). AAo, abdominal aorta; D, duodenum; SMA, superior
mesenteric artery.
B A
Figure 3 Upper gastrointestinal series. Upper gastrointestinal series in the supine position showed an abrupt cut-off (arrows) at the third
portion of the duodenum (A). In the prone position, the contrast medium passed through the obstructed part (arrows) of the distal side
(arrowheads) (B).
Ushiki et al. Journal of Medical Case Reports 2012, 6:14
http://www.jmedicalcasereports.com/content/6/1/14
Page 3 of 5Discussion
The clinical manifestation of a compression of the third
portion of the duodenum by SMA was initially
described by Rokitansky et al. in 1861 [4]. Subsequently,
Wilkie reported seven instances of SMA syndrome in
1927 [5] and his name has become a common eponym
for the SMA syndrome.
A number of case reports and several reviews have
been reported [1,2,6-11]. In general, most cases of SMA
syndrome in patients with neoplasms were due to
mechanical compression by intraabdominal tumor. How-
ever, severe weight loss results in reduction of the mesen-
teric fat pad, which can lead to compression of the
duodenum by the SMA. Cases of SMA syndrome due to
severe weight loss, such as trauma, eating disorders,
rheumatoid disease, cardiac cachexia, human immunode-
ficiency virus infection, and diabetes mellitus, have been
reported [6-11]. Neoplasms and systemic chemotherapy
can induce anorexia and body weight loss. Our case had
al o wB M Ib e f o r ec h e m o t h e r a p ya n ds h o w e daf u r t h e r
reduction in body weight after the initiation of che-
motherapy. Our search of the English medical literature
revealed no reports of SMA syndrome in patients receiv-
ing chemotherapy. To the best of our knowledge, this is
the first proven case of SMA syndrome precipitated by
weight loss due to NSCLC and chemotherapy. It is well
known that chemotherapy using cisplatin stimulates gas-
troduodenal vagal afferent nerves and is frequently asso-
ciated with emesis. We would like to emphasize that
SMA syndrome is a rare but noteworthy complication in
cancer patients, especially those presenting with severe
emesis and weight loss during chemotherapy. On the
other hand, there are several reports documenting
mesenteric vascular complications during systemic che-
motherapy using cisplatin [12,13]. Allerton described a
case of acute mesenteric ischemia after chemotherapy
using cisplatin [14]. Theref o r e ,w eh a v et od i s t i n g u i s h
SMA syndrome from acute mesenteric ischemia if a
patient complains of abdominal pain.
In patients with symptoms suggesting SMA syndrome,
further radiographic studies should be performed to
establish the diagnosis. The following strict radiographic
criteria have been established for diagnosis of SMA syn-
drome: (i) dilatation of the first and second portions of
the duodenum with or without gastric dilatation, (ii)
abrupt vertical and oblique compression of the mucosal
folds, (iii) antiperistaltic flow of contrast medium proxi-
mal to the obstruction, (iv) delay in transit of four to six
hours through the gastroduodenal region, and (v) relief
of obstruction in the prone, knee-chest, or left lateral
decubitus position [1]. The classic diagnostic procedure
is an upper gastrointestinal series. In patients with SMA
syndrome, upper gastrointestinal series shows duodenal
dilatation, retention of barium within the duodenum,
and characteristic vertical linear extrinsic pressure on
the third portion of the duodenum, but these findings
are nonspecific for the SMA syndrome [3].
Contrast-enhanced computed tomography (CT) scan
shows the advantage of providing an overall assessment
of the abdominal cavity. This is the best way to delineate
anatomical relationships and has been shown to be an
effective and noninvasive method for evaluating the aor-
tomesenteric angle, distance, fatty tissue, obstruction of
the duodenum, and potential culprits for compression
[15]. In normal individuals, the aortomesenteric angle
was reported to be 25° to 60° and the aortomesenteric
distance was reported to be 10 to 28 mm [3]. On the
other hand, subjects presenting with an aortomesenteric
angle of < 22° to 25° and distance of < 8 mm were
affected by SMA syndrome [16]. Cut-off values of SMA
syndrome were reported to be aortomesenteric angle of
22° (42.8% sensitivity and 100% specificity) and aortome-
senteric distance of 8 mm (100% sensitivity and specifi-
city) [17]. The measurement of the aortomesenteric angle
(15.8°) and aortomesenteric distance (6.1 mm) in our case
were consistent with the criteria for SMA syndrome.
Initial treatment of SMA syndrome usually involves a
conservative approach. Nasogastric drainage for gastric
decompression and mobilization into the prone or left
lateral decubitus position are effective in the acute set-
ting [1]. Both enteral jejunal feeding and total parenteral
nutrition have been useful for increases in body weight
promoting restoration of the retroperitoneal fat tissue
with consecutive increases in the aortomesenteric angle
and distance [1,18]. Surgical treatments, including open
or laparoscopic duodenojejunostomy or duodenal mobi-
lization and division of the ligament of Treitz, are nor-
mally indicated in symptomatic patients when
conservative treatment fails [1].
Conclusions
To the best of our knowledge, this is the first report of
SMA syndrome during cisplatin-containing chemother-
apy. Our case highlights the importance of considering
t h ep o s s i b i l i t yo fS M As y n d r o me in patients treated by
chemotherapy, especially those presenting with low BMI
and showing weight loss during chemotherapy. Con-
trast-enhanced computed tomography (CT) is a reliable
and noninvasive tool for diagnosis of SMA syndrome.
Total parenteral nutrition and tubal feeding with the
aim of increasing body weight are useful forms of treat-
ment in such cases.
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